Neurocrine Biosciences (NBIX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX)

NBIX 132.21

-0.3%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Billy Dunn who started this subject	6/18/2002 7:26:13 PM
From: mopgcw	Read Replies (2) of 1834

RESEARCH ALERT-Morgan Stanley starts Neurocrine NEW YORK, June 18 (Reuters) - Morgan Stanley said on Tuesday that it started coverage of Neurocrine Biosciences Inc. with an "equal-weight" rating and forecast that the will trade in line with its peers until later this year or early next year. Morgan Stanley analysts Ian Somaiya and Caroline Copithorne rate the biotechnology products industry, which includes Neurocrine, as "attractive." "We believe the valuation (of Neurocrine) is attractive based on several measures," the analysts said in a research note. "Our earnings estimates are based solely on the success of Indiplon for insomnia." Morgan Stanley, which has a $39 price target on Neurocrine shares, is forecasting a 2002 loss of $3.10 per share and a 2003 loss of $1.53 per share for the company. Neurocrine shares closed at $28.59 on Monday and have a 52-week trading range of $23.25 to $54.26. REUTERS

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next